153 related articles for article (PubMed ID: 17017895)
1. The guanylyl cyclase inhibition by MB as vasoplegic circulatory shock therapeutical target.
Evora PR; Viaro F
Curr Drug Targets; 2006 Sep; 7(9):1195-204. PubMed ID: 17017895
[TBL] [Abstract][Full Text] [Related]
2. Role of nitric oxide production in anaphylaxis and its relevance for the treatment of anaphylactic hypotension with methylene blue.
Evora PR; Simon MR
Ann Allergy Asthma Immunol; 2007 Oct; 99(4):306-13. PubMed ID: 17941276
[TBL] [Abstract][Full Text] [Related]
3. A review of methylene blue treatment for cardiovascular collapse.
Lo JC; Darracq MA; Clark RF
J Emerg Med; 2014 May; 46(5):670-9. PubMed ID: 24508113
[TBL] [Abstract][Full Text] [Related]
4. Guanylate cyclase inhibition by methylene blue as an option in the treatment of vasoplegia after a severe burn. A medical hypothesis.
Farina Junior JA; Celotto AC; da Silva MF; Evora PR
Med Sci Monit; 2012 May; 18(5):HY13-7. PubMed ID: 22534716
[TBL] [Abstract][Full Text] [Related]
5. Methylene blue: potential use of an antique molecule in vasoplegic syndrome during cardiac surgery.
Lenglet S; Mach F; Montecucco F
Expert Rev Cardiovasc Ther; 2011 Dec; 9(12):1519-25. PubMed ID: 22103871
[TBL] [Abstract][Full Text] [Related]
6. The effect of methylene blue on the hemodynamic changes during ischemia reperfusion injury in orthotopic liver transplantation.
Koelzow H; Gedney JA; Baumann J; Snook NJ; Bellamy MC
Anesth Analg; 2002 Apr; 94(4):824-9, table of contents. PubMed ID: 11916779
[TBL] [Abstract][Full Text] [Related]
7. Endothelial nitric oxide synthase is a key mediator of interleukin-2-induced hypotension and vascular leak syndrome.
Samlowski WE; Kondapaneni M; Tharkar S; McGregor JR; Laubach VE; Salvemini D
J Immunother; 2011 Jun; 34(5):419-27. PubMed ID: 21577143
[TBL] [Abstract][Full Text] [Related]
8. N(G)-nitro-L-arginine methyl ester, but not methylene blue, attenuates anaphylactic hypotension in anesthetized mice.
Takano H; Liu W; Zhao Z; Cui S; Zhang W; Shibamoto T
J Pharmacol Sci; 2007 Jul; 104(3):212-7. PubMed ID: 17598952
[TBL] [Abstract][Full Text] [Related]
9. Nitric oxide-independent activation of soluble guanylyl cyclase contributes to endotoxin shock in rats.
Wu CC; Chen SJ; Yen MH
Am J Physiol; 1998 Oct; 275(4):H1148-57. PubMed ID: 9746461
[TBL] [Abstract][Full Text] [Related]
10. Interleukin 1 activates soluble guanylate cyclase in human vascular smooth muscle cells through a novel nitric oxide-independent pathway.
Beasley D; McGuiggin M
J Exp Med; 1994 Jan; 179(1):71-80. PubMed ID: 7505803
[TBL] [Abstract][Full Text] [Related]
11. Methylene blue for clinical anaphylaxis treatment: a case report.
Rodrigues JM; Pazin Filho A; Rodrigues AJ; Vicente WV; Evora PR
Sao Paulo Med J; 2007 Jan; 125(1):60-2. PubMed ID: 17505688
[TBL] [Abstract][Full Text] [Related]
12. The Story of Nitric Oxide, Sepsis and Methylene Blue: A Comprehensive Pathophysiologic Review.
Saha BK; Burns SL
Am J Med Sci; 2020 Oct; 360(4):329-337. PubMed ID: 32631574
[TBL] [Abstract][Full Text] [Related]
13. Guanylate cyclase inhibition by methylene blue in circulatory shock caused by acute necrotizing pancreatitis: a word of caution based on a porcine model.
Baldo CF; Capellini VK; Celotto AC; Sônego F; Tirapelli LF; Batalhão M; Cárnio EC; dos Santos JS; Evora PR
Rev Col Bras Cir; 2013; 40(6):480-9. PubMed ID: 24573627
[TBL] [Abstract][Full Text] [Related]
14. Methylene blue, a soluble guanylyl cyclase inhibitor, reduces the sevoflurane minimum alveolar anesthetic concentration and decreases the brain cyclic guanosine monophosphate content in rats.
Masaki E; Kondo I
Anesth Analg; 1999 Aug; 89(2):484-9. PubMed ID: 10439772
[TBL] [Abstract][Full Text] [Related]
15. The selective guanylate cyclase inhibitor ODQ reduces multiple organ injury in rodent models of Gram-positive and Gram-negative shock.
Zacharowski K; Berkels R; Olbrich A; Chatterjee PK; Cuzzocrea S; Foster SJ; Thiemermann C
Crit Care Med; 2001 Aug; 29(8):1599-608. PubMed ID: 11505136
[TBL] [Abstract][Full Text] [Related]
16. Methylene blue administration in septic shock: a clinical trial.
Preiser JC; Lejeune P; Roman A; Carlier E; De Backer D; Leeman M; Kahn RJ; Vincent JL
Crit Care Med; 1995 Feb; 23(2):259-64. PubMed ID: 7532559
[TBL] [Abstract][Full Text] [Related]
17. Halothane attenuates nitric oxide relaxation of rat aortas by competition for the nitric oxide receptor site on soluble guanylyl cyclase.
Jing M; Ling GS; Bina S; Hart JL; Muldoon SM
Eur J Pharmacol; 1998 Jan; 342(2-3):217-24. PubMed ID: 9548389
[TBL] [Abstract][Full Text] [Related]
18. Methylene blue and epinephrine: a synergetic association for anaphylactic shock treatment.
Zheng F; Barthel G; Collange O; Montémont C; Thornton SN; Longrois D; Levy B; Audibert G; Malinovsky JM; Mertes PM
Crit Care Med; 2013 Jan; 41(1):195-204. PubMed ID: 23222265
[TBL] [Abstract][Full Text] [Related]
19. Characterization of NS 2028 as a specific inhibitor of soluble guanylyl cyclase.
Olesen SP; Drejer J; Axelsson O; Moldt P; Bang L; Nielsen-Kudsk JE; Busse R; Mülsch A
Br J Pharmacol; 1998 Jan; 123(2):299-309. PubMed ID: 9489619
[TBL] [Abstract][Full Text] [Related]
20. Hemodynamic and vascular endothelium function studies in healthy pigs after intravenous bolus infusion of methylene blue.
Menardi AC; Viaro F; Vicente WV; Rodrigues AJ; Evora PR
Arq Bras Cardiol; 2006 Oct; 87(4):525-32. PubMed ID: 17128324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
